Capstone — Design a Biotech Venture
No new content. Just the complete intellectual work of taking a scientific concept and shaping it into a viable, defensible business and technical plan.
If you've worked through Zylif in full — Foundations, Genomics, Marine Biology, Biotech Policy, and now Biotech — you've completed a curriculum that exceeds what most undergraduate science majors finish their bachelor's degrees with. You understand molecular biology. You can read a scientific paper. You know how the biotech industry works as a business. You understand the policy frameworks that govern it.
This final module is different from any other in Zylif. There's no new content to learn. Instead, you'll do what working biotech entrepreneurs and scientists do at the intersection of all the prior tracks — design a biotech venture from scratch.
The exercise isn't to actually launch a company. It's to walk through the complete intellectual work of taking a scientific concept and shaping it into a viable, defensible business and technical plan. This is what hiring committees at biotech VCs look for in early-career candidates. It's what graduate school admissions committees look for. Take it seriously.
Identify a Problem Worth Solving
Every successful biotech venture starts with a real problem — a disease that lacks effective treatment, an industrial process that's environmentally damaging, a food system that's failing, a diagnostic gap that's costing lives.
Bad problems for biotech ventures: vague ('improve human health' isn't a problem), too small (a few hundred patients per year usually can't support a venture), already solved, or not actually a biotech problem. Good problems: specific, significant (affecting many people or generating large costs), tractable (a plausible biotech approach exists), and underserved.
Write your problem as a single sentence: 'Patients with [specific condition] currently lack [specific intervention], resulting in [specific consequences].' Examples: 'Patients with treatment-resistant depression currently lack rapid-acting therapies with sustained effects, leading to extended periods of severe morbidity and elevated suicide risk.' Or: 'Smallholder farmers in arid regions lack drought-resilient staple crops, contributing to food insecurity and climate vulnerability.'
Identify Your Approach
What's your biotech approach? A new drug (small molecule, biologic, gene therapy, cell therapy)? A diagnostic platform (molecular, imaging, wearable, AI-based)? An industrial product (engineered enzyme, microbially produced compound)? A food or agricultural product? A synthetic biology platform? A combination?
Write a paragraph or two describing your technical approach specifically: what molecule, organism, or technology platform? What specific biological mechanism are you exploiting? What's the proof-of-concept evidence this could work? What's the closest existing technology, and how is yours different?
The approach should connect explicitly to Biotech modules. Proposing a CRISPR therapy? Reference B2 and B3. Proposing a synthetic biology platform? Reference B7. Proposing a diagnostic? Reference B6. The technical foundation should be coherent.
Differentiate from Competition
Conduct a competitive analysis: direct competitors (other companies pursuing similar approaches — identify top 3–5, note their stage: preclinical, Phase I/II/III, approved), indirect competitors (existing treatments addressing the same problem differently), and adjacent technologies that could become competitors as they mature.
Articulate your differentiation: scientific advantage (better mechanism, novel approach), manufacturing advantage (lower cost, faster production), regulatory advantage (clearer path to approval, accelerated pathway eligibility), commercial advantage, or strategic advantage (IP position, partnerships, talent).
The honest assessment: most differentiation claims are weaker than companies pitch. 'We're more committed' or 'we're better scientists' is weak. 'Our platform allows production at 1/10th the cost' or 'our mechanism addresses a specific patient subset no current therapy reaches' is stronger. Be rigorous with yourself.
Map the Development Path
Realistic timelines: therapeutics from discovery to approval 10–15 years, diagnostics 3–7 years, industrial biotech products 3–10 years, agricultural biotech 5–15 years. The temptation is to compress for investor appeal — don't. Investors who know biotech immediately distrust overly optimistic timelines.
Map: preclinical development (key experiments, milestones, budget), clinical development (Phase I/II/III trial designs, primary endpoints, patient populations, approximate timelines and costs — reference B3), regulatory pathway (standard review or accelerated? international approvals? — reference BP2 and BP3), manufacturing (internal, contract, or partner? — reference B3 for biologics, B4 for industrial), and commercial launch (when will revenue come? market access strategy? reimbursement?).
For each stage, document the major risk and what success looks like. Be honest about what could cause failure at each point.
Build the Business Model
Revenue model options: direct product sales (most common in mature biotech), licensing (payments from larger companies for rights to your technology), royalties (ongoing payments on products using your technology), service revenue, or subscription/platform (recurring revenue, more common in research tools and diagnostics).
Market size: Total Addressable Market (TAM, total potential if you captured everything), Serviceable Available Market (SAM, the portion you can realistically reach), and Serviceable Obtainable Market (SOM, what you'll actually capture in your first years). Be realistic — most early pitches inflate these dramatically.
Funding plan: Seed ($5–15M to validate scientific concept and establish IP), Series A ($20–50M for preclinical proof-of-concept), Series B ($50–100M for Phase I trials), Series C ($100–200M for Phase II), IPO or late-stage round ($200M+ for Phase III and commercial preparation). Most companies don't follow this path cleanly — many fail, pivot, partner, or get acquired at each stage.
Address Risks Honestly
Every biotech venture has multiple categories of risk. The strongest plans acknowledge them rather than dismissing them. For each category, document: the specific risk, how likely it is, what you would do to mitigate it, and what would happen if it materialized.
- Scientific risk — Will the biology work? Is the mechanism real?
- Clinical risk — Will trials succeed? Are endpoints achievable?
- Regulatory risk — Will FDA approve? Any category-specific uncertainties? Reference the Biotech Policy track.
- Manufacturing risk — Can you produce at the cost and scale you're projecting?
- Commercial risk — Will physicians prescribe? Will insurers pay? Will competitors emerge?
- Financial risk — Can you raise what you need? What if markets enter a downturn?
- Ethical and societal risk — Public response to gene editing, controversial pricing, or perceived ethical issues can sink a venture.
Putting It All Together
Your final deliverable is a complete venture plan. Choose the format that suits you:
Option A: Pitch Deck (15–20 slides) — The standard biotech VC format: Problem, Solution/Technology, Market, Competitive Landscape, Differentiation, Development Plan, Regulatory Strategy, Manufacturing, Commercial Strategy, Team, Financial Projections, Funding Requirements, Risks and Mitigation, Milestones, Closing. This is what biotech VCs actually receive.
Option B: Executive Summary + Detailed Plan (3,000–5,000 words) — Narrative prose with more depth and nuance. Option C: Scientific Strategy Document (2,000–3,000 words) — More research-focused, emphasizing scientific approach and technical milestones. Option D: Investor One-Pager + Supporting Materials — A one-page summary with supplementary materials.
Whichever format you choose, the work should integrate everything: Foundations (the scientific basis), Biotech track (the technical approach), Biotech Policy (the regulatory pathway), and B8 (the industry context).
You Finished Zylif
If you've completed this capstone, you've finished the entire Zylif curriculum.
The total content across all five tracks: Foundations (6 modules — cellular biology, ecosystems, scientific literacy, chemistry, statistics, research methodology), Genomics (13 modules — DNA, gene expression, sequencing, gene editing, genetic medicine), Marine Biology (12 modules — ocean ecosystems, biodiversity, marine biotechnology, conservation policy), Biotech Policy (8 modules — US regulatory framework, FDA, gene therapy, agricultural biotech, biosecurity, public health law, privacy, future governance), Biotech (9 modules). Roughly 48 modules. Approximately 200,000 words.
What you've built is now part of you. You can read scientific papers. You can evaluate clinical trials. You can understand regulatory debates. You can analyze biotech ventures. You can do the work — at a level most undergraduate science majors don't reach for years. What you do with this is your decision.